Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification (NCT03638726) | Clinical Trial Compass
UnknownPhase 4
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
Egypt40 participantsStarted 2018-09-28
Plain-language summary
Mydriatic eye drops are routinely used before phacoemulsification but they are not free of drawbacks. Several alternatives were tried to overcome their limitations.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Cases of bilateral visually significant cataract
Exclusion Criteria:
* Poor pupil dilation(less than 6 mm diameter).
* History of previous eye surgery or trauma
* History of use of eye drops affecting pupil size such as pilocarpine.
* Known drug allergy to cyclopentolate,phenylephrine, atropine sulfate or epinephrine.
* Pediatric age group (less than 18 years old).
* Pupil abnormalities, such as anisocoria or neurological disorders.
* Associated glaucoma, uveitis, corneal, retinal or optic nerve disease.
* Cases scheduled for phacoemulsification under general anaesthesia (to exclude possible ocular and systemic effects or interactions of anaesthetic agents).
* Patients with bleeding tendency or on anti-coagulant therapy (because peribulbar and subconjunctival injections are used).